The pharma company will present the the safety profile of phase two study and interim data of phase three study of human adenoviral vector-based platform vaccine candidate in the review process.
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.